Accurate determination of quadruplex binding affinity and potency of G-quadruplex-interactive telomerase inhibitors by use of a telomerase extension assay requires varying the primer concentration

Brian E. Cathers, Daekyu Sun, Laurence Hurley

Research output: Contribution to journalArticle

12 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)367-372
Number of pages6
JournalAnti-Cancer Drug Design
Volume14
Issue number4
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Anthraquinones
Telomerase
Guanine
Enzyme Inhibitors
Assays

Keywords

  • Anthraquinone
  • Assay
  • G-quadruplex
  • Inhibition
  • Telomerase

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Pharmacology

Cite this

@article{b6fa163348c543f187c312d5bf43f9b2,
title = "Accurate determination of quadruplex binding affinity and potency of G-quadruplex-interactive telomerase inhibitors by use of a telomerase extension assay requires varying the primer concentration",
keywords = "Anthraquinone, Assay, G-quadruplex, Inhibition, Telomerase",
author = "Cathers, {Brian E.} and Daekyu Sun and Laurence Hurley",
year = "1999",
month = "8",
language = "English (US)",
volume = "14",
pages = "367--372",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "4",

}

TY - JOUR

T1 - Accurate determination of quadruplex binding affinity and potency of G-quadruplex-interactive telomerase inhibitors by use of a telomerase extension assay requires varying the primer concentration

AU - Cathers, Brian E.

AU - Sun, Daekyu

AU - Hurley, Laurence

PY - 1999/8

Y1 - 1999/8

KW - Anthraquinone

KW - Assay

KW - G-quadruplex

KW - Inhibition

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=0032723367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032723367&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 367

EP - 372

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 4

ER -